APGE
Apogee Therapeutics, Inc.
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred
from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes.
Significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro.
Compare plans.
Beneficial ownership filing history
Showing 3 of 4 parsed filing(s) · 1 older require more history access| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management CIK0001897612 | Jun 30, 2026 observed Jul 8, 2026 filed · 8d Schedule 13G amendment | Reported reduction | 773.0K -9.5M | 12.00% -4.80 pts | $132.73 | $133.25 | |
| Fidelity / FMR CIK0000315066 | Jun 30, 2026 observed Jul 8, 2026 filed · 8d Schedule 13G amendment | Earliest Schedule 13G amendment found | 2.5K | 12.00% | $132.73 | $133.25 | |
| T. Rowe Price Investment Management CIK0001897612 | Mar 31, 2026 observed Apr 8, 2026 filed · 8d Schedule 13G amendment | Reported accumulation | 10.3M +4.1M | 16.80% +4.80 pts | $84.17 | $83.12 |